[go: up one dir, main page]

WO2016100803A3 - Methods of treating tissue calcification - Google Patents

Methods of treating tissue calcification Download PDF

Info

Publication number
WO2016100803A3
WO2016100803A3 PCT/US2015/066646 US2015066646W WO2016100803A3 WO 2016100803 A3 WO2016100803 A3 WO 2016100803A3 US 2015066646 W US2015066646 W US 2015066646W WO 2016100803 A3 WO2016100803 A3 WO 2016100803A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcification
npp1
treating tissue
provides
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/066646
Other languages
French (fr)
Other versions
WO2016100803A2 (en
Inventor
Anthony Quinn
Nelson HSIA
Tayeba KHAN
Kim Lynette ASKEW
Gregory Grabowski
Zhiliang Cheng
W. Charles O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP24165223.9A priority Critical patent/EP4438118A3/en
Priority to HK18105396.9A priority patent/HK1245662A1/en
Priority to CA2971414A priority patent/CA2971414A1/en
Priority to ES15871159T priority patent/ES2899895T3/en
Priority to EP21192925.2A priority patent/EP3967755B1/en
Priority to MX2017007946A priority patent/MX2017007946A/en
Priority to BR112017012928A priority patent/BR112017012928A2/en
Priority to EP15871159.8A priority patent/EP3234116B1/en
Priority to US15/536,880 priority patent/US10493135B2/en
Priority to US17/111,156 priority patent/USRE49529E1/en
Priority to JP2017531728A priority patent/JP7685309B2/en
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority to KR1020177019819A priority patent/KR102833432B1/en
Priority to AU2015364411A priority patent/AU2015364411A1/en
Priority to RU2017119466A priority patent/RU2770698C2/en
Priority to CN201580069537.6A priority patent/CN107109381A/en
Priority to KR1020257022841A priority patent/KR20250111233A/en
Publication of WO2016100803A2 publication Critical patent/WO2016100803A2/en
Publication of WO2016100803A3 publication Critical patent/WO2016100803A3/en
Priority to CONC2017/0006032A priority patent/CO2017006032A2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
PCT/US2015/066646 2014-12-19 2015-12-18 Methods of treating tissue calcification Ceased WO2016100803A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
JP2017531728A JP7685309B2 (en) 2014-12-19 2015-12-18 Methods for Treating Tissue Calcification
CA2971414A CA2971414A1 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
ES15871159T ES2899895T3 (en) 2014-12-19 2015-12-18 Tissue Calcification Treatment Procedures
EP21192925.2A EP3967755B1 (en) 2014-12-19 2015-12-18 Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
MX2017007946A MX2017007946A (en) 2014-12-19 2015-12-18 METHODS TO TREAT THE CALCIFICATION OF FABRICS.
BR112017012928A BR112017012928A2 (en) 2014-12-19 2015-12-18 use of an ectonucleotide pyrophosphatase phosphodiesterase (npp1); use of a pharmaceutical composition; and use of an isolated recombinant human snpp1, fragment or fusion protein thereof
EP15871159.8A EP3234116B1 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
US15/536,880 US10493135B2 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
KR1020177019819A KR102833432B1 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
EP24165223.9A EP4438118A3 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
HK18105396.9A HK1245662A1 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
US17/111,156 USRE49529E1 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
AU2015364411A AU2015364411A1 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
RU2017119466A RU2770698C2 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
CN201580069537.6A CN107109381A (en) 2014-12-19 2015-12-18 The method for treating tissue calcification
KR1020257022841A KR20250111233A (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification
CONC2017/0006032A CO2017006032A2 (en) 2014-12-19 2017-06-16 Methods to treat calcification of tissues

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462094943P 2014-12-19 2014-12-19
US62/094,943 2014-12-19
US201562249781P 2015-11-02 2015-11-02
US62/249,781 2015-11-02

Publications (2)

Publication Number Publication Date
WO2016100803A2 WO2016100803A2 (en) 2016-06-23
WO2016100803A3 true WO2016100803A3 (en) 2016-08-04

Family

ID=56127864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/066646 Ceased WO2016100803A2 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification

Country Status (15)

Country Link
US (2) US10493135B2 (en)
EP (3) EP3967755B1 (en)
JP (3) JP7685309B2 (en)
KR (2) KR20250111233A (en)
CN (1) CN107109381A (en)
AU (1) AU2015364411A1 (en)
BR (1) BR112017012928A2 (en)
CA (1) CA2971414A1 (en)
CO (1) CO2017006032A2 (en)
ES (2) ES2981606T3 (en)
HK (1) HK1245662A1 (en)
MX (3) MX2017007946A (en)
PL (1) PL3967755T3 (en)
RU (1) RU2770698C2 (en)
WO (1) WO2016100803A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2956163T3 (en) * 2013-02-13 2025-04-14 Yale University Compositions for treating pathological calcification and ossification
WO2016100803A2 (en) 2014-12-19 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
MX391074B (en) 2015-05-19 2025-03-21 Univ Yale COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CALCIFICATION CONDITIONS AND THEIR METHODS OF USE.
CA3005142A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
EP3493829B1 (en) 2016-08-05 2024-04-17 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
EP3790628A4 (en) * 2018-05-08 2022-03-09 Yale University COMPOSITIONS AND METHODS TO REDUCE PROGRESSION OF NEPHROLITHIASIS
AU2019327572B2 (en) 2018-08-31 2025-11-13 Yale University ENPP1 polypeptides and methods of using same
CA3126839A1 (en) * 2019-01-18 2020-07-23 Inozyme Pharma, Inc. Treatment of diseases involving deficiency of enpp1 or enpp3
CN113416258B (en) 2019-10-24 2023-08-29 北京免疫方舟医药科技有限公司 Multispecific antibody and preparation method and application thereof
KR20230042263A (en) * 2020-06-09 2023-03-28 이노자임 파마, 인코포레이티드 Soluble ENPP1 or ENPP3 Proteins and Uses Thereof
MX2023005836A (en) * 2020-11-19 2023-08-17 Inozyme Pharma Inc Treatment of enpp1 deficiency and abcc6 deficiency.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125182A1 (en) * 2011-03-11 2012-09-20 Synageva Biopharma Corp Npp1 fusion proteins
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (en) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
DK1032662T3 (en) 1997-11-07 2006-07-03 Trillium Therapeutics Inc Methods and Compositions for Immunomodulation
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1259649B1 (en) 2000-02-23 2009-11-04 Pxe international Inc. Methods and composition for diagnosing and treating pseudoxanthoma elasticum and related conditions
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
AU2003245664A1 (en) 2002-06-21 2004-01-06 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
SI1729795T1 (en) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
WO2016100803A2 (en) 2014-12-19 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
MX391074B (en) * 2015-05-19 2025-03-21 Univ Yale COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CALCIFICATION CONDITIONS AND THEIR METHODS OF USE.
CA3005142A1 (en) * 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125182A1 (en) * 2011-03-11 2012-09-20 Synageva Biopharma Corp Npp1 fusion proteins
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REZG, R ET AL.: "Inhibitors of Vascular Calcification as Potential Therapeutic Targets.", J NEPHROL., vol. 24, no. 4, July 2011 (2011-07-01), pages 416 - 427, XP055456534 *

Also Published As

Publication number Publication date
MX2023006083A (en) 2023-06-19
JP2018500315A (en) 2018-01-11
US10493135B2 (en) 2019-12-03
EP4438118A3 (en) 2024-12-04
MX2017007946A (en) 2017-09-15
KR20250111233A (en) 2025-07-22
EP3967755B1 (en) 2024-03-27
EP3234116A2 (en) 2017-10-25
JP2022003048A (en) 2022-01-11
EP3234116B1 (en) 2021-09-08
RU2017119466A (en) 2019-01-21
RU2770698C2 (en) 2022-04-21
RU2017119466A3 (en) 2019-12-20
JP7685309B2 (en) 2025-05-29
MX2022011281A (en) 2022-10-18
KR102833432B1 (en) 2025-07-14
KR20170095367A (en) 2017-08-22
US20180318400A1 (en) 2018-11-08
PL3967755T3 (en) 2024-08-19
EP3234116A4 (en) 2018-08-01
CN107109381A (en) 2017-08-29
WO2016100803A2 (en) 2016-06-23
USRE49529E1 (en) 2023-05-16
CO2017006032A2 (en) 2017-10-20
ES2981606T3 (en) 2024-10-09
EP3967755A1 (en) 2022-03-16
HK1245662A1 (en) 2018-08-31
JP2024010052A (en) 2024-01-23
ES2899895T3 (en) 2022-03-15
CA2971414A1 (en) 2016-06-23
AU2015364411A1 (en) 2017-06-08
BR112017012928A2 (en) 2018-05-15
EP4438118A2 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
WO2016100803A3 (en) Methods of treating tissue calcification
AU2018260809A1 (en) Compounds and uses thereof for the modulation of hemoglobin
BR112015009948A2 (en) activin-actria antagonists and uses for bone treatment and other disorders
AU2018260808A1 (en) Compounds and uses thereof for the modulation of hemoglobin
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
EA201990293A1 (en) MULTI-SPECIFIC ANTIBODIES AGAINST CD40 AND CD137
WO2016077397A3 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
HK1206040A1 (en) Anti-egfr antibodies and uses thereof
MX2015011509A (en) Compounds and uses thereof for the modulation of hemoglobin.
WO2016004389A3 (en) Monovalent binding proteins
HK1250238A1 (en) Anti-angptl8 antibodies and uses thereof
EA201791093A1 (en) ANTIBODIES TO CD47, METHODS AND USE
HK1197071A1 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2016090034A3 (en) Methods for b cell preconditioning in car therapy
BR112016022742A2 (en) compositions and methods for modulating growth hormone receptor expression
MX2018000352A (en) Substituted 4-azaindoles and their use as glun2b receptor modulators.
WO2016060564A8 (en) Body sculpting
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX2021015500A (en) Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators.
HK1254432A1 (en) Methods and compositions for treating fibrotic diseases
EP4268891A3 (en) Compound for use in methods for treatment of polycystic kidney disease
MX2020000636A (en) Synthetic proteins and therapeutic uses thereof.
WO2010033249A8 (en) Compositions of and methods of using ligand dimers
EP4328245A3 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15871159

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2015364411

Country of ref document: AU

Date of ref document: 20151218

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017531728

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/007946

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2971414

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: NC2017/0006032

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017012928

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015871159

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177019819

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017119466

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15871159

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112017012928

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170616

WWD Wipo information: divisional of initial pct application

Ref document number: 1020257022841

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020257022841

Country of ref document: KR